{"product_id":"sln-bcg-matrix","title":"(SLN) Silence Therapeutics plc BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Silence Therapeutics plc BCG Matrix helps you understand how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to unlock the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSLN360, Phase I cardiovascular lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN360 is Silence Therapeutics plc’s most visible standalone clinical asset and its Phase I lead for elevated lipoprotein(a), a risk factor linked to roughly 1 in 5 adults worldwide. That keeps it in the Stars bucket: high market potential, but still early clinical risk. If later-stage data stay strong, it could become the main value driver for Silence Therapeutics plc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSLN124, Phase I hematology lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN124 is a Phase I hematology lead that targets TMPRSS6, placing Silence Therapeutics plc in rare blood diseases with clear unmet need. Its main shots are non-transfusion-dependent thalassemia and myelodysplastic syndrome, both niche markets where better options can win fast. That makes SLN124 one of Silence Therapeutics plc’s strongest future differentiation bets in a Stars slot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emRNAi GOLD platform, liver-targeted RNAi engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003emRNAi GOLD is Silence Therapeutics plc’s core discovery engine, built for liver-targeted siRNA design against disease-causing genes. It underpins the pipeline and is the main growth driver because the platform can feed multiple programs from one technology base. In BCG terms, it fits a Star: high strategic value, clear differentiation, and centrality to future pipeline expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAstraZeneca, 4 disease areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAstraZeneca spans cardiovascular, renal, metabolic and respiratory diseases, four of the biggest and fastest-growing drug markets. Cardiovascular disease caused about 20.5 million deaths in 2021, and chronic kidney disease affects about 10% of adults worldwide, so the addressable pool is huge. For Silence Therapeutics, this deal adds reach and scale beyond its internal pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, durable demand\u003c\/li\u003e\n\u003cli\u003eMulti-disease commercial scale\u003c\/li\u003e\n\u003cli\u003eStronger partner-led reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRNAi platform, 2 clinical-stage assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s RNAi platform was backed by 2 named clinical programs by end-2025, giving the company a concentrated but high-upside pipeline. That matters because the lead assets drive most near-term value in biotech, while the platform can still spawn follow-on shots. In 2025, Silence reported cash, cash equivalents and short-term investments of about $202.9 million, supporting these programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 named clinical programs by end-2025\u003c\/li\u003e\n\u003cli\u003eHigh-conviction, focused pipeline\u003c\/li\u003e\n\u003cli\u003e$202.9 million cash and equivalents in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics’ Cash, Pipeline, and Platform Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s Stars are its two clinical leads and platform engine: SLN360, SLN124, and mRNAi GOLD. In 2025, the company held about $202.9 million in cash, cash equivalents and short-term investments, which helps fund these high-upside programs. AstraZeneca also broadens reach into large, fast-growing disease areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLN360\u003c\/td\u003e\n\u003ctd\u003ePhase I, Lp(a)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLN124\u003c\/td\u003e\n\u003ctd\u003ePhase I, rare blood disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emRNAi GOLD\u003c\/td\u003e\n\u003ctd\u003eCore RNAi platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix for Silence Therapeutics plc: identify Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClear BCG Matrix snapshot of Silence Therapeutics plc to quickly spot growth, cash, and drag areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Silence Therapeutics plc, helping users verify key claims quickly and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca collaboration, milestone cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstraZeneca collaboration cash is a core Cash Cow for Silence Therapeutics plc because it can deliver upfront payments, milestones, and funded development work without issuing new shares. That makes it non-dilutive cash, unlike pure internal R\u0026amp;D spend. In BCG terms, it is one of the clearest recurring funding engines in the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHansoh collaboration, 3 targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHansoh gives Silence Therapeutics plc 3 siRNA targets, so the platform keeps turning discovery into cash. The pact can shift part of the R\u0026amp;D bill to Hansoh and add milestone income later; deals of this type can reach up to US$1.8 billion in aggregate value, plus royalties. That makes it a clean monetization channel for the RNAi platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMallinckrodt partnership, complement disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s Mallinckrodt partnership targets complement cascade genes, giving the company a partnered route in complement-mediated disorders. This matters because such deals can convert research into shared commercialization cash flow, while Mallinckrodt funds much of the late-stage burden. That lowers Silence Therapeutics plc’s capital drag and keeps program risk off its own balance sheet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-funded R\u0026amp;D, non-dilutive model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc uses partner-funded R\u0026amp;D to reduce its own cash burn, so collaboration income can offset discovery and early development spend. For a pre-revenue biotech, that makes this the closest thing to a cash cow: in FY2025, the model kept dilution lower than fully self-funded pipelines while preserving pipeline access and shared risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners help fund R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eLower direct cash burn\u003c\/li\u003e\n\u003cli\u003eLess dilution than pure equity funding\u003c\/li\u003e\n\u003cli\u003eBest-fit cash engine for pre-revenue biotech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform licensing, recurring monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s platform licensing is the mature Cash Cow in its BCG mix: one siRNA platform can be out-licensed across liver and other disease areas, so revenue comes from repeat deals, upfront fees, milestones, and royalties rather than one-shot discovery wins. That makes monetization steadier and less binary, even if 2025\/2026 company filings still show the core value is in future partner-led deal flow, not product sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-asset out-licensing lowers single-program risk.\u003c\/li\u003e\n\u003cli\u003eRecurring deal terms improve cash visibility.\u003c\/li\u003e\n\u003cli\u003eBest fit for stable, mature monetization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics’ Cash Cow Deals Cut Burn and Dilution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s Cash Cows are partner-funded deals that turn its siRNA platform into recurring upfront fees, milestones, and shared R\u0026amp;D cash. In FY2025, this model helped offset burn and reduced dilution versus fully self-funded programs. Hansoh can cover up to US$1.8 billion in deal value, while AstraZeneca and Mallinckrodt keep cash flow tied to active programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHansoh\u003c\/td\u003e\n\u003ctd\u003eUp to US$1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding model\u003c\/td\u003e\n\u003ctd\u003eLower burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 impact\u003c\/td\u003e\n\u003ctd\u003eLess dilution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eSilence Therapeutics plc Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Silence Therapeutics plc BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no hidden changes—just the full, ready-to-use report. Once purchased, you’ll get immediate access to the final file for download, editing, or presentation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc ended 2025 with 0 approved medicines, so it had no marketed product to defend share in a mature market. That leaves no cash-generating asset to offset R\u0026amp;D burn or fund scale from sales. In BCG terms, this is a pure Dogs position: low market presence and no commercial moat yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 marketed brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc has 0 marketed brands, so it has no pharmacy or hospital sales to defend. That means its commercial footprint is still zero and there is no installed customer base, recurring product revenue, or brand-led share to protect. In 2025, this leaves the Dogs bucket driven by pipeline value only, not by any sold product base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Silence Therapeutics plc reported £0 product sales, so revenue was not driven by commercial product demand but by collaboration income. That means the business has no sales-backed operating engine yet, which is a classic Dogs sign in the BCG Matrix. With no product revenue base, market share remains low and scaling risk stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 mature royalty streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc has 0 mature royalty streams, so it gets no meaningful sales-based cash inflow today. With no approved launch, royalty income is still nil, and the company remains reliant on funding rounds and deal partners. That also limits self-funding; at 2025 year-end, the key question is burn, not royalties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 approved launches\u003c\/li\u003e\n\u003cli\u003eNo royalty cash flow\u003c\/li\u003e\n\u003cli\u003eDepends on financing\u003c\/li\u003e\n\u003cli\u003eWeak self-funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy commercial footprint absent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc is still research-led, not commercial-led: it has no approved product sales, no mature field sales force, and no proven launch or promotion engine. In BCG terms, this is not a low-growth cash cow with durable share; it is pre-commercial and depends on R\u0026amp;D execution.\u003c\/p\u003e\n\u003cp\u003eLatest filings still point to a company funded by pipeline progress, not market share, so the Dogs bucket does not fit a legacy business footprint. That matters because without distribution scale, there is no stable revenue base to defend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved product sales\u003c\/li\u003e\n\u003cli\u003eNo mature launch network\u003c\/li\u003e\n\u003cli\u003eNo durable commercial share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics Remains a Pure R\u0026amp;D Story, Not a Commercial One\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc fits Dogs in the BCG Matrix because it ended 2025 with £0 product sales, 0 approved launches, and 0 royalty cash flow. With no marketed brands or mature sales engine, it had no defendable market share or self-funding cash base. Its 2025 position stayed research-led, not commercial-led.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved launches\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e£0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty cash flow\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed brands\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSLN360, Phase I lipoprotein(a) risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN360 is still a Question Mark: in Phase 1, a single dose cut lipoprotein(a) by up to 98% over 150 days, but it has no outcomes data yet and clinical success is still unproven. Lp(a) is a huge market if it works, with about 20% of people worldwide carrying elevated levels, but Silence Therapeutics plc has not shown clear commercial fit. More data is needed, or the program can stall.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSLN124, Phase I non-transfusion-dependent thalassemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN124 in non-transfusion-dependent thalassemia is still in Phase I, so the data are too early to call it a Star or Cash Cow. Thalassemia is a serious rare-disease market, but uptake will hinge on clear safety and durable hemoglobin gains, especially if patients can avoid regular transfusions. For now, this looks like a classic invest-or-wait case for Silence Therapeutics plc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSLN124, Phase I myelodysplastic syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN124 is still in Phase I for myelodysplastic syndrome, so it has only early human data and no proven commercial traction yet. MDS is a high-unmet-need blood cancer setting, but Silence Therapeutics has not shown late-stage efficacy or approval, which keeps the asset in question-mark territory. The key test is whether early safety and target engagement can turn into durable response rates in a patient group where current options remain limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSLN124, planned polycythemia vera\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSLN124’s planned polycythemia vera program still sits in the Question Marks bucket: the asset has upside, but it is not yet de-risked by late-stage clinical data. Polycythemia vera is a rare hematology market, so a clean efficacy and safety signal could make it meaningful for Silence Therapeutics plc; until then, it remains a capital-consuming option.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eUpside depends on phase data.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRisk remains high today.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCash burn is likely to continue.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMallinckrodt complement program, early development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMallinckrodt’s complement-cascade program is still an early-stage bet, so it fits the Question Mark slot in Silence Therapeutics plc’s BCG matrix. At end-2025, there is no late-stage clinical proof yet, so the value case still rests on whether target biology and human data line up. One clean read: high upside, low evidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly stage\u003c\/li\u003e\n\u003cli\u003eNo late-stage proof\u003c\/li\u003e\n\u003cli\u003eHigh optionality\u003c\/li\u003e\n\u003cli\u003eStill more promise than proof\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly Promise, Still High Risk: Silence’s Catalysts Aren’t De-Risked Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s Question Marks are still all about future readouts, not proven sales: SLN360 cut lipoprotein(a) by up to 98% after one dose, but it is still Phase 1 and has no outcomes data. SLN124 in NTDT, MDS, and planned PV also remains early-stage, so upside is real but not de-risked. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eKey signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLN360\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eUp to 98% Lp(a) drop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLN124\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eEarly human data only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234918244617,"sku":"sln-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sln-bcg-matrix.webp?v=1785731816","url":"https:\/\/dcfanalyst.com\/products\/sln-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}